Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) - trimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCFfor drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) – trimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCFis a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
ED-B is predominantly expressed during angiogenesis and tumor growth. Onfekafusp Alfa is an immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells.
| Products Name (INN Index) | Pre-Made Onfekafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA) – trimer: Recombinant therapeutic |
|---|---|
| INN Name | onfekafusp alfa |
| Target | FN |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | [scFv – heavy – kappa] – trimer |
| VD LC | [scFv – heavy – kappa] – trimer |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Philogen (Sovicille Italy) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FN |
| Package |
